Interview with Jean Marimbert, Director General, Agence Française de Sécurité…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
Iris Pharma is a leading contract research organization (CRO) dedicated to ophthalmology, helping clients around the world navigate every stage of the drug and medical device development process – including in vivo ocular efficacy studies, Good Laboratory Practice (GLP) preclinical studies, bioanalysis, clinical trials, and marketing surveys. Specializing in offering preclinical and clinical research services worldwide, Iris Pharma has partnered with clients to bring nearly 70 ocular drugs and medical devices to market in the past 26 years. The company offers consulting services to help clients determine the best indication for molecules and products in development. Supporting clients ranging from small start-ups to large pharmaceutical companies and from newcomers to experts in eye therapy, Iris Pharma supports clients in every step of the process, ensuring that the preclinical development program supports the intended clinical trial design and therapeutic use.
Contact
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
